We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Tarsus Pharmaceuticals Inc
7 own
4 watching
Current Price
$54.04
$-0.37
(-0.68%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,011.15M
52-Week High
56.77000
52-Week Low
18.99000
Average Volume
0.13M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,011.15M52-Week High56.7700052-Week Low18.99000Average Volume0.13MDividend Yield--P/E Ratio--What does the Tarsus Pharmaceuticals Inc do?
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More
How much money does Tarsus Pharmaceuticals Inc make?
News & Events about Tarsus Pharmaceuticals Inc.
Globe Newswire
1 year ago
Webcast scheduled for Thursday, June 15 at 8:30am PTIRVINE, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, ...
Globe Newswire
2years ago
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Tarsus will be added to the NASDAQ...
Globe Newswire
2years ago
Positive Phase 1b Callisto data shows that TP-05 is well tolerated and safety data supports progression to Phase 2a Phase 2a Carpo trial to evaluate the safety, tolerability, and proof-of-activity of TP-05 in healthy subjects TP-05 designed to be an on-demand, long-acting prophylactic treatment that...
Zolmax
2years ago
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS Get Rating) CFO Leonard M. Greenstein sold 5,000 shares of the businesss stock in a transaction on Thursday, October 20th. The stock was sold at an average price of $15.92, for a total value of $79,600.00. Following the transaction, the chief ...
Globe Newswire
2years ago
Saturn-2 follow-up data to be presented on TP-03 for the treatment of Demodex blepharitis Tarsus recently submitted NDA to the FDA for TP-03 Data from an investigator-initiated trial evaluating meibomian gland atrophy in patients with Demodex blepharitis will also be presented IRVINE, Calif., Oct. ...
Frequently Asked Questions
Frequently Asked Questions
What is Tarsus Pharmaceuticals Inc share price today?
Can Indians buy Tarsus Pharmaceuticals Inc shares?
How can I buy Tarsus Pharmaceuticals Inc shares from India?
Can Fractional shares of Tarsus Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Tarsus Pharmaceuticals Inc stocks?
What is today’s traded volume of Tarsus Pharmaceuticals Inc?
What is today’s market capitalisation of Tarsus Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Tarsus Pharmaceuticals Inc?
What percentage is Tarsus Pharmaceuticals Inc down from its 52-Week High?
What percentage is Tarsus Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$54.04
$-0.37
(-0.68%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.